Literature DB >> 21336532

Insulin resistance influences the association of adiponectin levels with diabetes incidence in two population-based cohorts: the Cooperative Health Research in the Region of Augsburg (KORA) S4/F4 study and the Framingham Offspring Study.

M-F Hivert1, L M Sullivan, P Shrader, C S Fox, D M Nathan, R B D'Agostino, P W F Wilson, B Kowall, C Herder, C Meisinger, B Thorand, W Rathmann, J B Meigs.   

Abstract

AIMS/HYPOTHESIS: Lower adiponectin levels are associated with higher risk of incident type 2 diabetes. Most analyses have been adjusted for confounding factors, but few have taken into account insulin resistance per se. We tested the hypothesis that the association of adiponectin levels with incident type 2 diabetes differs between insulin-resistant and insulin-sensitive individuals.
METHODS: We studied two prospective cohorts: the Framingham Offspring Study (n = 2,023) and the Cooperative Health Research in the Region of Augsburg (KORA) S4/F4 study (n = 887) cohorts. Insulin resistance was estimated by HOMA-insulin resistance (HOMA-IR). We used logistic regression analysis to test the association between adiponectin and incident type 2 diabetes overall and in insulin-resistant vs insulin-sensitive individuals (defined by ≥ vs <75th percentile of HOMA-IR).
RESULTS: At baseline, Framingham's participants were 60 ± 9 years old and 56% were women; KORA's participants were 63 ± 5 years old and 49% were women. Type 2 diabetes incidence was 5.4% over 6.5 years (n = 109) in Framingham and 10.5% over 8 years (n = 93) in KORA. Lower adiponectin levels were associated with type 2 diabetes incidence in both cohorts. In insulin-resistant individuals, lower adiponectin levels were associated with higher risk of type 2 diabetes incidence (OR 1.60 [95% CI 1.10-2.31] per SD decrease in Framingham, p = 0.01; and OR 2.34 [95% CI 1.16-4.73] in KORA, p = 0.02); while this was not observed in insulin-sensitive individuals (OR 1.10 [95% CI 0.73-1.67] in Framingham, p = 0.64; and OR 1.34 [95%CI: 0.88-2.03] in KORA, p = 0.18). CONCLUSIONS/
INTERPRETATION: We conclude that lower adiponectin levels are associated with higher risk of type 2 diabetes in insulin-resistant but not in insulin-sensitive individuals. This suggests that some level of insulin resistance is needed to see deleterious effects of low adiponectin.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21336532      PMCID: PMC3223124          DOI: 10.1007/s00125-011-2067-y

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  14 in total

1.  Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III).

Authors: 
Journal:  JAMA       Date:  2001-05-16       Impact factor: 56.272

2.  Hypoadiponectinemia and proinflammatory state: two sides of the same coin?: results from the Cooperative Health Research in the Region of Augsburg Survey 4 (KORA S4).

Authors:  Christian Herder; Hans Hauner; Burkhard Haastert; Karin Röhrig; Wolfgang Koenig; Hubert Kolb; Sylvia Müller-Scholze; Barbara Thorand; Rolf Holle; Wolfgang Rathmann
Journal:  Diabetes Care       Date:  2006-07       Impact factor: 19.112

3.  High prevalence of undiagnosed diabetes mellitus in Southern Germany: target populations for efficient screening. The KORA survey 2000.

Authors:  W Rathmann; B Haastert; A Icks; H Löwel; C Meisinger; R Holle; G Giani
Journal:  Diabetologia       Date:  2003-02-18       Impact factor: 10.122

4.  Adipokines and risk of type 2 diabetes in older men.

Authors:  S Goya Wannamethee; Gordon D O Lowe; Ann Rumley; Lynne Cherry; Peter H Whincup; Naveed Sattar
Journal:  Diabetes Care       Date:  2007-02-23       Impact factor: 19.112

5.  Circulating concentrations of the adipocyte protein adiponectin are decreased in parallel with reduced insulin sensitivity during the progression to type 2 diabetes in rhesus monkeys.

Authors:  K Hotta; T Funahashi; N L Bodkin; H K Ortmeyer; Y Arita; B C Hansen; Y Matsuzawa
Journal:  Diabetes       Date:  2001-05       Impact factor: 9.461

6.  Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man.

Authors:  D R Matthews; J P Hosker; A S Rudenski; B A Naylor; D F Treacher; R C Turner
Journal:  Diabetologia       Date:  1985-07       Impact factor: 10.122

7.  Incidence of Type 2 diabetes in the elderly German population and the effect of clinical and lifestyle risk factors: KORA S4/F4 cohort study.

Authors:  W Rathmann; K Strassburger; M Heier; R Holle; B Thorand; G Giani; C Meisinger
Journal:  Diabet Med       Date:  2009-12       Impact factor: 4.359

8.  Adiponectin and the development of type 2 diabetes: the atherosclerosis risk in communities study.

Authors:  Bruce B Duncan; Maria Inês Schmidt; James S Pankow; Heejung Bang; David Couper; Christie M Ballantyne; Ron C Hoogeveen; Gerardo Heiss
Journal:  Diabetes       Date:  2004-09       Impact factor: 9.461

9.  Plasma adiponectin is an independent predictor of type 2 diabetes in Asian indians.

Authors:  Chamukuttan Snehalatha; Bheekamchand Mukesh; Mary Simon; Vijay Viswanathan; Steven M Haffner; Ambady Ramachandran
Journal:  Diabetes Care       Date:  2003-12       Impact factor: 19.112

10.  Adiponectin and development of type 2 diabetes in the Pima Indian population.

Authors:  Robert S Lindsay; Tohru Funahashi; Robert L Hanson; Yuji Matsuzawa; Sachiyo Tanaka; P Antonio Tataranni; William C Knowler; Jonathan Krakoff
Journal:  Lancet       Date:  2002-07-06       Impact factor: 79.321

View more
  15 in total

1.  Associations of GDF-15 and GDF-15/adiponectin ratio with odds of type 2 diabetes in the Chinese population.

Authors:  Xiaoying Wu; Wenting Xuan; Lili You; Hong Lian; Feng Li; Xiaoyun Zhang; Qingyu Chen; Kan Sun; Chaogang Chen; Mingtong Xu; Yan Li; Li Yan; Xiuwei Zhang; Meng Ren
Journal:  Endocrine       Date:  2021-03-12       Impact factor: 3.633

2.  Epidemiology in Germany-general development and personal experience.

Authors:  Heinz-Erich Wichmann
Journal:  Eur J Epidemiol       Date:  2017-08-16       Impact factor: 8.082

3.  Effects of basal insulin application on serum visfatin and adiponectin levels in type 2 diabetes.

Authors:  Wei-Dong Wang; Lin Xing; Jun-Ru Teng; Shuo Li; N A Mi
Journal:  Exp Ther Med       Date:  2015-04-17       Impact factor: 2.447

4.  Adiponectin and the incidence of type 2 diabetes in Hispanics and African Americans: the IRAS Family Study.

Authors:  Anthony J G Hanley; Lynne E Wagenknecht; Jill M Norris; Richard Bergman; Andrea Anderson; Y Ida Chen; Carlos Lorenzo; Steven M Haffner
Journal:  Diabetes Care       Date:  2011-08-04       Impact factor: 19.112

5.  Total and high-molecular-weight adiponectin and risk of incident diabetes in older people.

Authors:  Jorge R Kizer; Alice M Arnold; David Benkeser; Joachim H Ix; Luc Djousse; Susan J Zieman; Joshua I Barzilay; Russell P Tracy; Christos S Mantzoros; David S Siscovick; Kenneth J Mukamal
Journal:  Diabetes Care       Date:  2011-12-06       Impact factor: 19.112

6.  Effect of therapeutic dose of vitamin d on serum adiponectin and glycemia in vitamin d-insufficient or deficient type 2 diabetic patients.

Authors:  Nima Baziar; Kurosh Jafarian; Zhaleh Shadman; Mostafa Qorbani; Mohsen Khoshniat Nikoo; Mahshid Abd Mishani
Journal:  Iran Red Crescent Med J       Date:  2014-09-05       Impact factor: 0.611

7.  Circulating adiponectin levels and risk of type 2 diabetes in the Japanese.

Authors:  S Yamamoto; Y Matsushita; T Nakagawa; T Hayashi; M Noda; T Mizoue
Journal:  Nutr Diabetes       Date:  2014-08-18       Impact factor: 5.097

8.  A genome-wide approach accounting for body mass index identifies genetic variants influencing fasting glycemic traits and insulin resistance.

Authors:  Alisa K Manning; Marie-France Hivert; Robert A Scott; Jonna L Grimsby; Nabila Bouatia-Naji; Han Chen; Denis Rybin; Ching-Ti Liu; Lawrence F Bielak; Inga Prokopenko; Najaf Amin; Daniel Barnes; Gemma Cadby; Jouke-Jan Hottenga; Erik Ingelsson; Anne U Jackson; Toby Johnson; Stavroula Kanoni; Claes Ladenvall; Vasiliki Lagou; Jari Lahti; Cecile Lecoeur; Yongmei Liu; Maria Teresa Martinez-Larrad; May E Montasser; Pau Navarro; John R B Perry; Laura J Rasmussen-Torvik; Perttu Salo; Naveed Sattar; Dmitry Shungin; Rona J Strawbridge; Toshiko Tanaka; Cornelia M van Duijn; Ping An; Mariza de Andrade; Jeanette S Andrews; Thor Aspelund; Mustafa Atalay; Yurii Aulchenko; Beverley Balkau; Stefania Bandinelli; Jacques S Beckmann; John P Beilby; Claire Bellis; Richard N Bergman; John Blangero; Mladen Boban; Michael Boehnke; Eric Boerwinkle; Lori L Bonnycastle; Dorret I Boomsma; Ingrid B Borecki; Yvonne Böttcher; Claude Bouchard; Eric Brunner; Danijela Budimir; Harry Campbell; Olga Carlson; Peter S Chines; Robert Clarke; Francis S Collins; Arturo Corbatón-Anchuelo; David Couper; Ulf de Faire; George V Dedoussis; Panos Deloukas; Maria Dimitriou; Josephine M Egan; Gudny Eiriksdottir; Michael R Erdos; Johan G Eriksson; Elodie Eury; Luigi Ferrucci; Ian Ford; Nita G Forouhi; Caroline S Fox; Maria Grazia Franzosi; Paul W Franks; Timothy M Frayling; Philippe Froguel; Pilar Galan; Eco de Geus; Bruna Gigante; Nicole L Glazer; Anuj Goel; Leif Groop; Vilmundur Gudnason; Göran Hallmans; Anders Hamsten; Ola Hansson; Tamara B Harris; Caroline Hayward; Simon Heath; Serge Hercberg; Andrew A Hicks; Aroon Hingorani; Albert Hofman; Jennie Hui; Joseph Hung; Marjo-Riitta Jarvelin; Min A Jhun; Paul C D Johnson; J Wouter Jukema; Antti Jula; W H Kao; Jaakko Kaprio; Sharon L R Kardia; Sirkka Keinanen-Kiukaanniemi; Mika Kivimaki; Ivana Kolcic; Peter Kovacs; Meena Kumari; Johanna Kuusisto; Kirsten Ohm Kyvik; Markku Laakso; Timo Lakka; Lars Lannfelt; G Mark Lathrop; Lenore J Launer; Karin Leander; Guo Li; Lars Lind; Jaana Lindstrom; Stéphane Lobbens; Ruth J F Loos; Jian'an Luan; Valeriya Lyssenko; Reedik Mägi; Patrik K E Magnusson; Michael Marmot; Pierre Meneton; Karen L Mohlke; Vincent Mooser; Mario A Morken; Iva Miljkovic; Narisu Narisu; Jeff O'Connell; Ken K Ong; Ben A Oostra; Lyle J Palmer; Aarno Palotie; James S Pankow; John F Peden; Nancy L Pedersen; Marina Pehlic; Leena Peltonen; Brenda Penninx; Marijana Pericic; Markus Perola; Louis Perusse; Patricia A Peyser; Ozren Polasek; Peter P Pramstaller; Michael A Province; Katri Räikkönen; Rainer Rauramaa; Emil Rehnberg; Ken Rice; Jerome I Rotter; Igor Rudan; Aimo Ruokonen; Timo Saaristo; Maria Sabater-Lleal; Veikko Salomaa; David B Savage; Richa Saxena; Peter Schwarz; Udo Seedorf; Bengt Sennblad; Manuel Serrano-Rios; Alan R Shuldiner; Eric J G Sijbrands; David S Siscovick; Johannes H Smit; Kerrin S Small; Nicholas L Smith; Albert Vernon Smith; Alena Stančáková; Kathleen Stirrups; Michael Stumvoll; Yan V Sun; Amy J Swift; Anke Tönjes; Jaakko Tuomilehto; Stella Trompet; Andre G Uitterlinden; Matti Uusitupa; Max Vikström; Veronique Vitart; Marie-Claude Vohl; Benjamin F Voight; Peter Vollenweider; Gerard Waeber; Dawn M Waterworth; Hugh Watkins; Eleanor Wheeler; Elisabeth Widen; Sarah H Wild; Sara M Willems; Gonneke Willemsen; James F Wilson; Jacqueline C M Witteman; Alan F Wright; Hanieh Yaghootkar; Diana Zelenika; Tatijana Zemunik; Lina Zgaga; Nicholas J Wareham; Mark I McCarthy; Ines Barroso; Richard M Watanabe; Jose C Florez; Josée Dupuis; James B Meigs; Claudia Langenberg
Journal:  Nat Genet       Date:  2012-05-13       Impact factor: 38.330

9.  Lower adiponectin levels at first trimester of pregnancy are associated with increased insulin resistance and higher risk of developing gestational diabetes mellitus.

Authors:  Marilyn Lacroix; Marie-Claude Battista; Myriam Doyon; Julie Ménard; Jean-Luc Ardilouze; Patrice Perron; Marie-France Hivert
Journal:  Diabetes Care       Date:  2013-01-08       Impact factor: 19.112

10.  Circulating peroxiredoxin 4 and type 2 diabetes risk: the Prevention of Renal and Vascular Endstage Disease (PREVEND) study.

Authors:  Ali Abbasi; Eva Corpeleijn; Ron T Gansevoort; Rijk O B Gans; Joachim Struck; Janin Schulte; Hans L Hillege; Pim van der Harst; Ronald P Stolk; Gerjan Navis; Stephan J L Bakker
Journal:  Diabetologia       Date:  2014-06-04       Impact factor: 10.122

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.